Live Deals
Active Portfolio
Enabling precision genetic medicine
2019 Seed+
2017 Seed
2017 Seed
- Universal delivery platform for gene therapies
- Rapid, affordable, targeted to specific cell types
- Disrupting $100B+ Hematology Market
Helping global populations live chronic disease-free
2018 Seed
- Digital diabetes prevention 2X effective as drugs
- Reducing risk of Type-2 Diabetes by 60%
- International partnership with Merck KGaA
Crowdsourcing medical expertise
2016 Seed
- Solving elusive cases (avg: 6+ years, 8+ doctors)
- 1M+ unique monthly visitors
- 5-18X ROI for doctors/health plans/employers
Revolutionizing the way the world views science
2017 Series A
2016 Seed
2016 Seed
- World’s first hybrid microscope
- Easy-to-use, stunning digital display
- 8X increase in researcher productivity
Disruptive Approach to ALS with Potential to be First Viable Treatment for Patients
2019 Seed
- Potential to Slow/halt Progression of ALS
- Funding and Strategic Support from Amgen Ventures
- World-class Team (Medtronic, J&J, Harvard, MIT)
BV Showcase
Repurposing natural skin microbes to combat inflammatory skin diseases
- Improved efficacy without the harsh side effects
- Wide ranging therapeutic & cosmetic applications
- Major US markets: Psoriasis ($5B), Acne ($3B), D..
The Bioverge platform is host to both Regulation Crowdfunding and Regulation D offering types. Reg CF offerings are provided by Bioverge Portal LLC and Reg D offering are provided by Bioverge Funds Management LLC. Companies designated as BV Showcase are enrolled in a program managed by Bioverge Inc and are not associated with an offering on the Bioverge platform.